ImmunityBio (IBRX) Free Cash Flow (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Free Cash Flow data on file, last reported at -$76.5 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 11.0% year-over-year to -$76.5 million in Q1 2026; TTM through Mar 2026 was -$296.8 million, a 19.78% increase from a year earlier, with the FY2025 full-year figure at -$306.3 million, up 21.94% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$76.5 million, down from -$71.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for IBRX reached as high as -$67.2 million in Q3 2025 and fell as low as -$134.6 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$91.5 million across 5 years, with a median of -$85.9 million in 2025.
• Across the five-year window, Free Cash Flow tumbled 93.66% in 2022 and jumped 42.3% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$109.7 million in 2022, then advanced by 6.43% to -$102.6 million in 2023, then rose by 20.59% to -$81.5 million in 2024, then advanced by 12.69% to -$71.1 million in 2025, then dropped by 7.48% to -$76.5 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$76.5 million in Q1 2026, -$71.1 million in Q4 2025, and -$67.2 million in Q3 2025.